Skip Navigation


International Immunology Advance Access originally published online on July 28, 2007
International Immunology 2007 19(9):1083-1093; doi:10.1093/intimm/dxm076
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/9/1083    most recent
dxm076v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Yang, W
Right arrow Articles by Junghans, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, W
Right arrow Articles by Junghans, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2007. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML)

W Yang1, EL Beaudoin1, L Lu1, RA Du Pasquier2, MJ Kuroda2, RA Willemsen3, IJ Koralnik2 and RP Junghans1

1 Division of Surgical Research, Department of Surgery, Boston University School of Medicine, Roger Williams Medical Center, Providence, RI 02908, USA
2 Division of Viral Pathogenesis and Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
3 Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands

Correspondence to: R. P. Junghans; E-mail: rjunghans{at}rwmc.org

Progressive multifocal leukoencephalopathy (PML) is a deadly brain disease caused by the polyomavirus JC (JCV). The aim of this study is to develop ‘designer T cells’ armed with anti-JCV TCR-based chimeric immune receptors (CIRs) by gene modification for PML immunotherapy. Two T cell lines specific to two dominant CTL epitopes derived from JCV VP1 protein (termed p36 and p100) from an HLA-A0201+ PML survivor were generated for TCR cloning. Two distinct dominant TCR alpha chains (V{alpha}6 and V{alpha}12) and a unique TCR beta chain (Vß5.1) were cloned from the p36-specific cell line, while only one alpha (V{alpha}8.6) and one beta (Vß2) chains were dominant in the p100-specific line. Retroviral constructs encoding CIRs were created with the extracellular domains of TCR {alpha} and ß chains fused to the transmembrane and cytoplasmic portions of CD3{zeta} (V{alpha}C{alpha}CD3{zeta} or VßCßCD3{zeta}). Cellular expression and screening for binding specific peptide-HLA-A0201 tetramer confirmed the reactivity of the p100 TCR{alpha}ß and of one of the two pairs of p36 TCR{alpha}ß (V{alpha}12 and Vß5.1). Functional tests confirmed CIR-expressing T cells secreted cytokines and expressed potent cytotoxicity on contact with A0201+ B-lymphoblastoid line loaded with peptides and/or with HLA-A0201+ cells expressing native JCV VP1 protein. In conclusion, anti-JCV designer T cells were generated.

Keywords: gene transfer, retroviral transduction, T cell, TCR

Transmitting editor: G. Trinchieri

Received 22 December 2006, accepted 14 June 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.